Metformin treatment
Phase 3Small molecule
Metformin treatment is one of 124 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.
4
Indications
6
Total Trials
2
Active Trials
123
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Metformin treatment
KKristian Karstoft
Phase 3
Actemra
RochePreclinical
Rituxan
RochePreclinical
Cimzia
UCBPreclinical
Simponi
Johnson & JohnsonPreclinical
Remicade
OOrganon and Co
Preclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ilaris
NovartisPreclinical
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Interaction2 trials
Cognitive impairment1 trial
Metformin Treatment on Cognitive Impairment of Schizophrenia
Recruiting·—·Phase 3·NCT05838573·120 enrolled
Autism1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metformin treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKristian Karstoft